02185 BIOHEART-B
- 2.150
- +0.130+6.44%
BIOHEART-B News
百心安-B：2023年報
Baixinan-B (02185.HK) lost about 189 million yuan in 2023
Gelonghui, March 25 | Baixinan-B (02185.HK) announced that for the year ended December 31, 2023, the Group's net loss was approximately RMB 188.8 million, a decrease of 18.2% from approximately RMB 230.9 million in 2022. R&D expenditure for the year ended 31 December 2023 was approximately RMB 111.7 million, a decrease of 29.2% from approximately RMB 157.8 million recorded in 2022. As of December 31, 2023, the net asset liability ratio was 5.4% (2022:6.8%).
BIOHEART-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Baixinan-B (02185.HK) plans to hold a board meeting on March 25 to approve the annual results
Gelonghui, March 13 | Baixinan-B (02185.HK) announced that the company will hold a board meeting on March 25, 2024 (Monday) to review and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider the proposed payment of a final dividend (if any).
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Changes in Hong Kong stocks | Baixinan-B (02185) rose nearly 7% Medtronic RDN products were approved in the US, and the company's RDN products are progressing ahead in China
Baixinan-B (02185) rose nearly 7%. As of press release, it was up 6.99% to HK$4.44, with a turnover of HK$1,218,000.
After more than ten years of experience, Medtronic RDN was approved to begin commercialization
Compared to other Red Sea markets, this RDN circuit, which is still in the Blue Ocean market, not only has global medical device giants betting, but also many excellent domestic local companies struggling to catch up.
CITIC Construction Investment: Innovative pharmaceutical companies are still optimistic about segments such as prescription drugs and medical devices on the high-value investment track
The Zhitong Finance App learned that CITIC Construction Investment released a research report stating that last week it focused on reviewing the mid-term business conditions of pharmaceutical companies and innovative pharmaceutical companies.
BIOHEART-B: 2023 INTERIM REPORT
Shanghai Bio-heart Biological Technology's Loss Narrows in H1
Shanghai Bio-heart Biological Technology (HKG:2185) incurred a loss attributable to owners of 86.2 million yuan for the first half, narrowing from 101.4 million yuan in the prior year.
BIOHEART-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
Medical Device Biz Attracts High-end Manufacturers
China's high-end manufacturers are making inroads into the domestic medical device sector, injecting impetus into its high-quality development.
Baixinan-B (02185.HK) plans to hold a board meeting on August 11 to approve interim results
On August 1, August 1, 丨Baixinan-B (02185.HK) announced that the company will hold a board meeting on August 11, 2023 (Friday) to review and approve (among others) the interim results and announcements of the company and its subsidiaries for the six months ended June 30, 2023, and consider the payment of interim dividends (if any).
BIOHEART-B: DATE OF BOARD MEETING
CIT2023|iberis-htn research first launched! Global leadership, innovative research and development
Surprisingly, a number of leading local RDN companies have begun to go overseas, leading the way in innovative research and development, and have been highly recognized by overseas academics.
Bioheart (02185.HK) Announces Clinical Result for Iberis-HTN at CIT 2023
SHANGHAI, June 29, 2023 /PRNewswire/ -- Bioheart (02185.HK), together with its holding subsidiary Angiocare announces the clinical result for Iberis-HTN at China Interventional Therapeutics 2023.
Baixinan (02185.HK) announces Iberis HTN clinical results at CIT 2023
SHANGHAI, June 30, 2023 /PRNewswire/ -- Baixinan (02185.HK) and its holding subsidiary Antong Healthcare announced the clinical results of Iberis HTN at the 21st China Interventional Cardiology Conference (CIT 2023) in 2023. Iberis HTN (NCT02901704) is a prospective, multicenter, blind, randomized controlled trial to evaluate the safety and efficacy of the Iberis multi-electrode renal artery radiofrequency ablation catheter system for primary hypertension. The study was conducted by Academician Gao Runlin of Fuwai Hospital and Jiang Xiong
Analysis
Price Target
No Data
